Related Experiment Video
Updated: Jun 17, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Inhaled BDP/formoterol extra-fine combination. Evidence and future perspectives
1Respiratory Medicine & Research Centre on Asthma and COPD, University of Ferrara. ppa@unife.it
Pneumologie (Stuttgart, Germany)
|December 17, 2009
Summary
A new extra-fine asthma inhaler combines beclometasone and formoterol. This advanced formulation improves lung deposition, allowing for a lower corticosteroid dose and an enhanced safety profile in managing persistent asthma.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Respiratory Therapeutics
Background:
- Inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA) are primary treatments for moderate to severe persistent asthma.
- These medications target inflammation and bronchodilation, key components of asthma management.
- Potential for synergistic effects exists when both drug classes reach their targets simultaneously.
Purpose of the Study:
- To evaluate a novel extra-fine formulation of beclometasone dipropionate (BDP) and formoterol fumarate (F).
- To assess the impact of extra-fine particle size on lung deposition and therapeutic efficacy.
- To determine the risk-benefit profile of this new combination therapy.
Main Methods:
- Randomized clinical trials involving patients with moderate to severe persistent asthma.
- Assessment of efficacy and safety of the extra-fine BDP/F formulation.
- Comparison with existing fixed-combination asthma therapies.
Main Results:
- The extra-fine formulation demonstrated increased deposition in peripheral airways.
- A greater proportion of the inhaled medication reached its pharmacological target.
- The BDP/F extra-fine combination was found to be as effective as other fixed combinations.
- A potential for reduced ICS dosage and improved risk-benefit profile was observed.
Conclusions:
- The extra-fine BDP/F formulation offers an effective treatment option for moderate to severe persistent asthma.
- Improved lung deposition enhances therapeutic delivery and potentially allows for dose reduction.
- This new formulation maintains efficacy comparable to existing treatments with an improved safety profile.
Related Concept Videos
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation